According to the results of the current study, based on a limited sample of clinically suspected aMCI and mild AD subjects, combining APOE genotypes and plasma Aβ1–42 increases the accuracy for detecting amyloid PET+ in early stage AD from 42.3 to 70.4%. This evidence concerns the gene APOE and Alzheimer disease.